Company Information

LINCOLN PHARMACEUTICALS LTD.

NSE : LINCOLNBSE : 531633ISIN CODE : INE405C01035Industry : Pharmaceuticals & DrugsHouse : Private
BSE597.700.65 (+0.11 %)
PREV CLOSE ( ) 597.05
OPEN PRICE ( ) 599.35
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1731
TODAY'S LOW / HIGH ( )592.95 607.10
52 WK LOW / HIGH ( )365.4 754.25
NSE596.90-3.45 (-0.57 %)
PREV CLOSE( ) 600.35
OPEN PRICE ( ) 595.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 596.90 (20)
VOLUME 22877
TODAY'S LOW / HIGH( ) 591.25 608.35
52 WK LOW / HIGH ( )365.25 755.15
ChairmanKishor M Shah
Managing DirectorMahendra G Patel
Company SecretaryTrusha Shah
Non Executive Independent DirectorSaurin J Parikh
Whole Time DirectorHashmukhbhai Ishwarlal Patel
Munjal M Patel
Ashish Patel
Non Independent & Non Executive DirectorRajnikant G Patel
Incorporation Year : 20-01 1995

Registered Office :

Address : Lincoln House", Behind Satyam Complex,Science City Road,Sola Ahmedabad,
Gujarat-380060 .

Phone : 079-41078000

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,Ahmedabad

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.